Instituto Cardiovascular de Rosario

Institution (Healthcare)

Homepage ROR

Also Known As

Cardiovascular Institute of Rosario, Instituto Cardiovascular de Rosario

Publications

49.8K

Citations

Authors

181

Concepts

About

Instituto Cardiovascular de Rosario is a healthcare institution in Rosario, Argentina known for medicine, cardiovascular disease, and public health.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	31	102	11.8K
2	Public Health	16	33	4.3K
3	Health Sciences	4	13	448
4	Engineering	3	11	429
5	Management	1	1	18

Instituto Cardiovascular de Rosario

Publications

49.8K

Citations

Page 1

	Year	Citations
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome Gregory G. Schwartz, Philippe Gabríel Steg, Michael Szarek, New England Journal of Medicine	2018	3.3K
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease John W. Eikelboom, Stuart J. Connolly, Jackie Bosch, New England Journal of Medicine	2017	2.3K
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial Christina Davies, Hongchao Pan, Jon Godwin, The Lancet Breast OncologyLong-term EffectsMedicineRandomised TrialGynecology	2012	2K
Prognostic value of grip strength: findings from the Prospective Urban Rural Epidemiology (PURE) study Darryl P. Leong, Koon Teo, Sumathy Rangarajan, The Lancet Prognostic ValueClinical EpidemiologyRural HealthEpidemiologic ResearchGrip Strength	2015	1.8K
Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease Deepak L. Bhatt, Michael Szarek, Bertram Pitt, New England Journal of Medicine	2020	1.1K
Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study Koon Teo, Stephanie Ôunpuu, Steven Hawken, The Lancet Tobacco CessationTobacco ControlCoronary Heart DiseaseHealth PolicyCardiovascular Disease	2006	991
Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial Alexandre Mebazaa, Beth A. Davison, Ovidiu Chioncel, The Lancet Heart FailureStructural Heart DiseaseCardiovascular DiseasePatient SafetyCardiovascular Pharmacology	2022	882
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial Sonia S. Anand, Jackie Bosch, John W. Eikelboom, The Lancet ThrombosisCardiovascular DiseaseStrokeMedicinePlacebo-controlled Trial	2017	855
Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease Salim Yusuf, Jackie Bosch, Gilles R. Dagenais, New England Journal of Medicine	2016	827
Effects of Aspirin Dose When Used Alone or in Combination With Clopidogrel in Patients With Acute Coronary Syndromes Ron J.G. Peters, Shamir R. Mehta, Keith A.A. Fox, Circulation	2003	702

Page 1